Services on Demand
Journal
Article
Indicators
- Cited by SciELO
Related links
- Similars in SciELO
Share
Medicina (Buenos Aires)
Print version ISSN 0025-7680
Abstract
SEOANE, Leonardo; BARANCHUK, Adrián and CONDE, Diego. Vernakalant en la reversión de la fibrilación auricular de reciente comienzo. Medicina (B. Aires) [online]. 2015, vol.75, n.4, pp.239-244. ISSN 0025-7680.
Atrial fibrillation (AF) is the most common sustained arrhythmia. Cardioversion is considered one of the best treatments for recent onset AF, especially with drugs for avoiding sedation. Vernakalant is a novel antiarrhythmic that acts selectively in the atrium, and inhibits potassium currents, with minor blockade of IKr currents in the ventricle. It has been recently approved for pharmacological cardioversion of recent-onset AF in the European Union. The aim of this review is to analyze the pharmacokinetic and pharmacodynamic of vernakalant, and to show the efficacy and safety of this drug for the conversion of AF to sinus rhythm.
Keywords : Vernakalant; Recent-onset atrial fibrillation; Ion channels; Pharmacological cardioversion.